XOMA is engaged in the discovery and development of antibody-based therapeutics. The company's product candidates include: X213, an allosteric inhibitor of prolactin action and humanized IgG1-Kappa monoclonal antibody that binds to the extracellular domain of the human prolactin receptor; and XMetA, which is an insulin receptor-activating antibody designed to provide reduction of hyperglycemia in Type 2 diabetic patients. The company also has two oncology and oncology-related preclinical product candidates: interleukin 2, which for metastatic melanoma and renal cell carcinoma; and anti-parathyroid receptor portfolio, which is a G-protein-coupled receptor involved in the regulation of calcium metabolism.
  • TickerXOMA
  • ISINUS98419J2069
  • ExchangeNASDAQ Stock Market
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States

Analysts

ValuEngine Rating and Forecast Report for XOMA

ValuEngine Rating and Forecast Report for XOMA

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Laura Chico
  • Liana Moussatos
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Laura Chico
  • Liana Moussatos
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

ValuEngine Rating and Forecast Report for XOMA

ValuEngine Rating and Forecast Report for XOMA

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Laura Chico
  • Liana Moussatos
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Laura Chico
  • Liana Moussatos
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Laura Chico
  • Liana Moussatos
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Laura Chico
  • Liana Moussatos
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Laura Chico
  • Liana Moussatos
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Laura Chico
  • Liana Moussatos
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

ValuEngine Rating and Forecast Report for XOMA

ValuEngine Rating and Forecast Report for XOMA

ValuEngine Rating and Forecast Report for XOMA

ValuEngine Rating and Forecast Report for XOMA

ValuEngine Rating and Forecast Report for XOMA

ValuEngine Rating and Forecast Report for XOMA

ValuEngine Rating and Forecast Report for XOMA

ValuEngine Rating and Forecast Report for XOMA

ValuEngine Rating and Forecast Report for XOMA

ValuEngine Rating and Forecast Report for XOMA

MarketLine Department

Ionis Pharmaceuticals, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments

Summary Marketline's Ionis Pharmaceuticals, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Ionis Pharmaceuticals, Inc. since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competi...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch